Usinger Lotte, Ibsen Hans, Linneberg Allan, Azizi Michel, Flambard Bénédicte, Jensen Lars T
Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital Glostrup, Glostrup, Denmark.
Clin Physiol Funct Imaging. 2010 Mar;30(2):162-8. doi: 10.1111/j.1475-097X.2009.00921.x. Epub 2010 Jan 26.
Milk fermented by lactic acid bacteria is suggested to have antihypertensive effect in humans. In vitro and animal studies have established an angiotensin-converting enzyme (ACE) inhibitor effect of peptides in fermented milk. However, other modes of action must be considered, because until today no human studies have confirmed an ACE inhibition in relation to the intake of fermented milk.
We undertook a double-blinded randomized placebo-controlled study including 94 borderline-hypertensive persons to study the effect on human physiology of Lactobacillus helveticus fermented milk. The subjects were randomized into three groups: Cardi04-300 ml, Cardi04-150 ml or placebo. All components of the renin-angiotensin-aldosterone system were measured several times. Sympathetic activity was estimated by plasma noradrenaline and cardiovascular response to head-up tilt at baseline and after 8 weeks of intervention.
No ACE inhibition of the fermented milk was demonstrated, as none of the components of the renin-angiotensin-aldosteron system changed. Plasma noradrenaline response to tilt test after intervention stayed unchanged between groups (P = 0.38), but declined in the group Cardi04-300 from 2.01 +/- 0.93 nmol l(-1) at baseline to 1.49 +/- 0.74 nmol l(-1) after 8 weeks (P = 0.002). There was no change in 24-h ambulatory blood pressure or heart rate between groups.
Despite a known ACE inhibitory effect in vitro and in animals, milk fermented with Lb. helveticus did not inhibit ACE in humans. Our results suggest that the intake of fermented milk decreases sympathetic activity, although not to an extent mediating reductions of blood pressure and heart rate in borderline-hypertensive subjects.
乳酸菌发酵乳被认为对人体有降血压作用。体外和动物研究已证实发酵乳中的肽具有血管紧张素转换酶（ACE）抑制作用。然而，必须考虑其他作用方式，因为迄今为止尚无人体研究证实摄入发酵乳与ACE抑制之间的关系。
我们进行了一项双盲随机安慰剂对照研究，纳入94名临界高血压患者，以研究瑞士乳杆菌发酵乳对人体生理的影响。受试者被随机分为三组：Cardi04 - 300毫升组、Cardi04 - 150毫升组或安慰剂组。多次测量肾素 - 血管紧张素 - 醛固酮系统的所有成分。通过血浆去甲肾上腺素和基线及干预8周后对直立倾斜试验的心血管反应来评估交感神经活动。
未证明发酵乳有ACE抑制作用，因为肾素 - 血管紧张素 - 醛固酮系统的任何成分均未改变。干预后各组间对倾斜试验的血浆去甲肾上腺素反应保持不变（P = 0.38），但Cardi04 - 300组从基线时的2.01±0.93纳摩尔/升降至8周后的1.49±0.74纳摩尔/升（P = 0.002）。各组间24小时动态血压或心率无变化。
尽管在体外和动物中已知有ACE抑制作用，但瑞士乳杆菌发酵乳在人体中并未抑制ACE。我们的结果表明，摄入发酵乳可降低交感神经活动，尽管程度不足以介导临界高血压受试者血压和心率的降低。
